Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Nichi-Iko's net income FY 2012-2018

Net income of Nichi-Iko Pharmaceutical Co., Ltd. in fiscal years 2012 to 2018 (in billion Japanese yen)*

by Statista Research Department, last edited Sep 24, 2019
Nichi-Iko's net income FY 2012-2018 The statistic shows the net income of Nichi-Iko Pharmaceutical Co., Ltd. in fiscal years 2012 to 2018. In fiscal year 2018, the Japanese generics manufacturer Nichi-Iko Pharmaceutical generated a net income of nearly 6.9 billion Japanese yen, down from about 8.1 billion yen in the previous fiscal year.
Show more

Net income of Nichi-Iko Pharmaceutical Co., Ltd. in fiscal years 2012 to 2018 (in billion Japanese yen)*

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.